Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Emsley, Robin | - |
dc.contributor.author | Ahokas, Antti | - |
dc.contributor.author | Suarez, Aldo | - |
dc.contributor.author | Marinescu, Dragos | - |
dc.contributor.author | Doci, Ivan | - |
dc.contributor.author | Lehtmets, Andres | - |
dc.contributor.author | Milanova, Vihra | - |
dc.contributor.author | Lee, Min Soo | - |
dc.contributor.author | Didi, Roy | - |
dc.contributor.author | Araszkiewicz, Aleksander | - |
dc.contributor.author | Sulaiman, Ahmad Hatim | - |
dc.contributor.author | Blanchot, Francoise Picarel | - |
dc.contributor.author | Crutel, Veronique Strijckmans | - |
dc.contributor.author | Antoine, Catherine | - |
dc.contributor.author | Penelaud, Pierre-Francois | - |
dc.date.accessioned | 2021-09-02T09:12:56Z | - |
dc.date.available | 2021-09-02T09:12:56Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-07 | - |
dc.identifier.issn | 0160-6689 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/74452 | - |
dc.description.abstract | Objective: The present placebo-controlled study evaluated the efficacy and safety of 8 weeks of treatment with tianeptine 25-50 mg/d in elderly patients suffering from major depressive disorder (MDD) according to DSM-IV-TR. Escitalopram 5-10 mg/d was used as an active comparator. Methods: Elderly outpatients aged at least 65 years with a primary diagnosis of moderate to severe episode of recurrent MDD were recruited by psychiatrists in 44 clinical centers in 10 countries from October 2013 to January 2016. Patients were randomly assigned to receive tianeptine (n=105), placebo (n=107), or escitalopram (n=99) for 8 weeks. The primary outcome measure was the 17-item Hamilton Depression Rating Scale (HDRS17) total score. Results: Tianeptine improved depressive symptoms, as evaluated by the HDRS17 total score in terms of absolute change from baseline (week 0) to week 8 (placebo-tianeptine difference [SE] of 3.84 [0.85] points, P <.001, using a last-observation-carried-forward approach) and response to treatment (tianeptine: 46.7%; placebo: 34.0%, estimate [SE]=12.70% [6.70], P=.06). A sensitivity analysis using a mixed model for repeated measures confirmed the main results on HDRS total score. The placebo-tianeptine difference (SE) was 0.66 (0.15) for Clinical Global Impressions-Severity of Illness (95% CI, 0.37 to 0.96; P <.001) and 0.57 (0.14) for Clinical Global Impressions-Improvement (95% CI, 0.30 to 0.83; P <.001). Positive results were also obtained with the active control escitalopram (HDRS17 total score placebo-escitalopram difference of 4.09 +/- 0.86 points, P <.001), therefore validating the sensitivity of the studied population. Tianeptine was well tolerated, with only minimal differences in tolerability from placebo. Conclusions: The present study provides robust evidence that an 8-week treatment period with tianeptine 25-50 mg is efficacious and well tolerated in depressed patients aged 65 years or older. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PHYSICIANS POSTGRADUATE PRESS | - |
dc.subject | LATE-LIFE DEPRESSION | - |
dc.subject | CONTROLLED-RELEASE PAROXETINE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | GERIATRIC OUTPATIENTS | - |
dc.subject | SAFETY | - |
dc.subject | TOLERABILITY | - |
dc.subject | VENLAFAXINE | - |
dc.subject | FLUOXETINE | - |
dc.subject | DULOXETINE | - |
dc.subject | SERTRALINE | - |
dc.title | Efficacy of Tianeptine 25-50 mg in Elderly Patients With Recurrent Major Depressive Disorder: An 8-Week Placebo- and Escitalopram-Controlled Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Min Soo | - |
dc.identifier.doi | 10.4088/JCP.17m11741 | - |
dc.identifier.scopusid | 2-s2.0-85052612756 | - |
dc.identifier.wosid | 000452890900004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PSYCHIATRY, v.79, no.4 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PSYCHIATRY | - |
dc.citation.title | JOURNAL OF CLINICAL PSYCHIATRY | - |
dc.citation.volume | 79 | - |
dc.citation.number | 4 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Psychology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychology, Clinical | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | LATE-LIFE DEPRESSION | - |
dc.subject.keywordPlus | CONTROLLED-RELEASE PAROXETINE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | GERIATRIC OUTPATIENTS | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | VENLAFAXINE | - |
dc.subject.keywordPlus | FLUOXETINE | - |
dc.subject.keywordPlus | DULOXETINE | - |
dc.subject.keywordPlus | SERTRALINE | - |
dc.subject.keywordAuthor | Antidepressants | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | Geriatric Psychiatry | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.